viewLineage Cell Therapeutics

Lineage Cell Therapeutics busy working on treatments relating to Dry AMD and spinal cord injury

Lineage Cell Therapeutics (NYSE AMERICAN: LCTX) CEO Brian Culley and CFO Brandi Roberts joined Steve Darling from Proactive to share details about their proprietary cell-based therapy platform. The Company is using that platform to advance a pipeline of novel candidates for the treatment of advanced dry age-related macular degeneration, spinal cord injuries, and cancer.

Both Culley and Roberts discussed recent clinical developments and provided an overview of the Company’s balance sheet. Lineage will be a featured company on Proactive’s next One2One Virtual conferences.

Quick facts: Lineage Cell Therapeutics

Price: 1.105 USD

Market: NYSE
Market Cap: $165.73 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lineage Cell Therapeutics named herein, including the promotion by the Company of Lineage Cell Therapeutics in any Content on the Site, the...


Proactive's One2One Virtual Investor Forum - Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc. (NYSEAMERICAN:LCTX) CEO Brian Culley and CFO Brandi Roberts present to investors at Proactive's One2One Virtual Investor Forum on October 14th, 2020. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet...

2 weeks, 2 days ago

2 min read